This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Asif, G.
Right arrow Articles by Schinazi, R. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Asif, G.
Right arrow Articles by Schinazi, R. F.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 2007, p. 2877-2882, Vol. 51, No. 8
0066-4804/07/$08.00+0     doi:10.1128/AAC.00193-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Pharmacokinetics of the Antiviral Agent ß-D-2'-Deoxy-2'-Fluoro-2'-C-Methylcytidine in Rhesus Monkeys{triangledown} ,{dagger}

Ghazia Asif,1,3 Selwyn J. Hurwitz,1,3 Junxing Shi,3,{ddagger} Brenda I. Hernandez-Santiago,1,3 and Raymond F. Schinazi1,2,3*

Department of Pediatrics,1 Yerkes National Primate Research Center, Emory University, Atlanta, Georgia 30322,2 Veterans Affairs Medical Center, Decatur, Georgia 300333

Received 8 February 2007/ Returned for modification 30 April 2007/ Accepted 31 May 2007

ß-D-2'-Deoxy-2'-fluoro-2'-C-methylcytidine (PSI-6130) is an effective inhibitor of hepatitis C virus (HCV) replication in vitro. The purpose of this study was to evaluate the single-dose pharmacokinetics of PSI-6130 in rhesus monkeys following intravenous (i.v.) and oral administration. Noncompartmental analysis of the serum data obtained following oral and i.v. administration was performed. Pharmacokinetic studies with rhesus monkeys indicated slow and incomplete absorption with a mean absorption time (MAT) of 4.6 h and an oral bioavailability of 24.0% ± 14.3% (mean ± standard deviation), with comparable mean apparent half-lives following i.v. (4.54 ± 3.98 h) and oral (5.64 ± 1.13 h) administrations. The average percentages of the total dose recovered unchanged and in deaminated form in the urine were 32.9% ± 12.6% and 18.9% ± 6.6% (i.v.) and 6.0% ± 3.9% and 3.9% ± 1.0% (oral), respectively. The total bioavailability, taking into account the parent drug and its deaminated metabolite 2'-deoxy-2'-fluoro-2'-C-methyluridine (PSI-6206), was 64% ± 26%. PSI-6130 was present in the cerebrospinal fluid after oral and i.v. dosing. However, no deamination of radiolabeled PSI-6130 was detected after 8 h of incubation in monkey and human whole blood. An N4-modified prodrug of PSI-6130 (PSI-6419) was orally administered to monkeys, but it failed to improve the oral bioavailability of PSI-6130. Further studies are warranted to improve the oral bioavailability and reduce the deamination of PSI-6130 in order to explore the potential of this drug for the treatment of HCV-infected individuals.

* Corresponding author. Mailing address: Veterans Affairs Medical Center, Medical Research 151H, 1670 Clairmont Road, Decatur, GA 30033. Phone: (404) 728-7711. Fax: (404) 728-7726. E-mail: rschina{at}emory.edu

{triangledown} Published ahead of print on 11 June 2007.

{dagger} Dedicated to our friend and colleague, Harold M. McClure (1937 to 2004).

{ddagger} Present address: RFS Pharma LLC, Tucker, GA 30084.

Antimicrobial Agents and Chemotherapy, August 2007, p. 2877-2882, Vol. 51, No. 8
0066-4804/07/$08.00+0     doi:10.1128/AAC.00193-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.





Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»